TC
VKTX icon

Titleist Capital’s Viking Therapeutics VKTX Stock Holding History

Titleist Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$132K Buy
+14,000
New +$62.5K 0.03% 228

Other funds holding VKTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Titleist Capital's VKTX Position: Q4 2022 in Review

Titleist Capital opened a new position in Viking Therapeutics (VKTX) in Q4 2022: 14,000 shares worth $132K. The stake represents 0.03% of the portfolio and ranks #228 among its holdings.

129 funds tracked by Wall St. Rank hold VKTX as of Q4 2022.

  • Titleist Capital held 14,000 shares of Viking Therapeutics worth $132K as of Q4 2022.
  • Viking Therapeutics was a new Titleist Capital position in Q4 2022.
  • Viking Therapeutics made up 0.03% of Titleist Capital's portfolio in Q4 2022, its #228 holding.
  • 129 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2022.

Based on Titleist Capital's 13F filing for Q4 2022, filed 12 Jan 2023.